Abstract: A tumor treating fields system and an associated insulated electrode includes at least one electrode sheet applying an alternating electric signal; and an electrical connector detachably connected with the sheet, the sheet includes an individual electrode unit and a first wire connected with the electrode unit, the sheet is detachably connected with the electrical connector through the first wire. The sheet of the insulated electrode is detachably connected with the electrical connector through the first wire, and the sheet includes one electrode unit. When the electrode unit is damaged and is nonfunctional, only the damaged sheet is replaced, reducing the cost of tumor treatment. The electrode units are combined in quantity or adjusted in position according to a patient's tumor site, position and tumor size, to ensure the coverage area for tumor treating fields therapy performed by the insulated electrodes, enhancing the electric field strength for tumor treating fields therapy.

Abstract: A tumor treating fields system includes an electric field generator, generating a plurality of alternating current signals; at least two pairs of insulated electrodes, each of the electrodes includes a plurality of electrode sheets, and an electrical connector with a switching circuit including switches that are respectively connected with the plurality of sheets, each sheet has a temperature sensor; and an adapter, transmitting the plurality of alternating current signals to the respective switch of the switching circuit of the corresponding electrode, the switch individually controls an electrical connection of the adapter to the corresponding sheet to selectively apply the alternating current signals. The present system individually controls each sheet electrically connected with the switching circuit to selectively apply the alternating current signals to the corresponding sheet.

Abstract: A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.

Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.

Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.

Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.